CSPC Pharmaceutical Group Ltd 2022 SR
The report highlights CSPC's commitment to pharmaceutical innovation, investing RMB 3.987 billion in R&D and launching the world's first mitoxantrone hydrochloride liposome injection. It details progress in COVID-19 mRNA vaccines and small-molecule inhibitors. The company emphasizes its "green and sustainable development" strategy, aiming for significant reductions in emissions and energy consumption by 2025. Social initiatives include the "CSPC LEADING" research fund and medical assistance for children in distress. Governance is strengthened through an ESG improvement mechanism and performance evaluations linked to sustainability targets.
Company: CSPC Pharmaceutical Group Ltd
Sector: Health Care
Country: China
Year: 2022
Type: SR
Pages: 111
Back to company
CSPC Pharmaceutical Group Ltd
Corporate Social Responsibility Report
The report highlights CSPC's commitment to pharmaceutical innovation, investing RMB 3.987 billion in R&D and launching the world's first mitoxantrone hydrochloride liposome injection. It details progress in COVID-19 mRNA vaccines and small-molecule inhibitors. The company emphasizes its "green and sustainable development" strategy, aiming for significant reductions in emissions and energy consumption by 2025. Social initiatives include the "CSPC LEADING" research fund and medical assistance for children in distress. Governance is strengthened through an ESG improvement mechanism and performance evaluations linked to sustainability targets.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Mar 22, 2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Workplace Fatalities
Net Zero Target
Employees